FindTrial
Sign In

Pemetrexed Accord 500 mg powder for concentrate for solution for infusion.

DRUG3 trials

Sponsors

Incyte Corp., Summit Therapeutics Inc., Universitair Ziekenhuis Gent

Conditions

Metastatic nonsquamous or squamous non-small cell lung cancerPatients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatmentmetastatic non-small-cell lung cancer

Phase 1

A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)
Not yet recruitingCTIS2025-521577-13-00
Universitair Ziekenhuis Gentmetastatic non-small-cell lung cancer
Target: 64Updated: 2025-09-11

Phase 3

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)
Active, not recruitingCTIS2023-504434-22-00
Summit Therapeutics Inc.Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Start: 2023-10-03Target: 45Updated: 2025-12-16
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
Active, not recruitingCTIS2022-501987-16-00
Incyte Corp.Metastatic nonsquamous or squamous non-small cell lung cancer
Start: 2020-10-02Target: 14Updated: 2025-08-05